Adc Therapeutics SA (ADCT) — 10-Q Filings
All 10-Q filings from Adc Therapeutics SA. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
ADCT Narrows Q3 Loss, But 9-Month Deficit Widens Amid Restructuring
— Nov 10, 2025 Risk: high
ADC Therapeutics SA (ADCT) reported a net loss of $40.966 million for the three months ended September 30, 2025, a slight improvement from the $43.969 million n -
ADC Therapeutics' Net Loss Widens to $95.2M Amid Restructuring Costs
— Aug 12, 2025 Risk: high
ADC Therapeutics SA reported a net loss of $95.248 million for the six months ended June 30, 2025, a significant increase from the $83.150 million net loss in t -
ADC Therapeutics SA Files Q1 2025 10-Q Report
— May 14, 2025 Risk: medium
ADC Therapeutics SA filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter -
ADC Therapeutics SA Files Q3 2024 10-Q Report
— Nov 7, 2024 Risk: medium
ADC Therapeutics SA filed its Q3 2024 10-Q report on November 7, 2024, covering the period ending September 30, 2024. The filing details the company's financial -
ADC Therapeutics SA Files Q2 2024 10-Q
— Aug 6, 2024 Risk: medium
ADC Therapeutics SA filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of 2024 -
ADC Therapeutics SA Files 10-Q for Period Ending March 31, 2024
— May 6, 2024 Risk: low
ADC Therapeutics SA (ADCT) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. ADC Therapeutics SA filed a 10-Q report for the period ending March 31,
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX